Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

Authors:

Abstract
The tumor suppressor gene CDKN2A encodes p16INK4a and p14ARF which regulate cell cycle progression, and is frequently deleted in cancer. Homozygous deletion (homdel) of CDKN2A has been incorporated as a Grade 4 defining criterion for IDH-mutant gliomas without 1p-/19q-codeletion (IDHmut-noncodel) in the WHO CNS5 classification.1 However, the prognostic value of hemizygous CDKN2A deletions (hemidel) is unclear. We assessed copy number variation profiles of initial (n = 1256) and recurrent (n = 494) IDHmut gliomas to evaluate the impact of CDKN2A hemidel on overall survival (OS) outcomes ( Figure 1).
Funding Information
  • National Institutes of Health (R01CA237208, R21NS114873, R21CA256575, U2CCA252979, P30CA034196)
  • Deutsche Forschungsgemeinschaft
  • William Guy Forbeck Research Foundation